Access Bio
Key metrics
Earnings
| Revenue, Q3 2026 | ₩10m |
|---|---|
| Revenue QoQ | +47.8% |
| Revenue YoY | +277.5% |
| Operating income, Q3 2026 | -₩5m |
| Operating income QoQ | +66.7% |
| Operating income YoY | +45.8% |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩39.3bn |
| Treasury shares cancelled (number), last 12 months | 2,553,998 shares |
| Treasury shares cancelled, last 12 months, % of shares | 7.3% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 0 shares |
| Potential new shares, last 12 months | 0 shares |
| Potential new shares, % of shares | 0.0% |
| Conversion price adjustments, last 12 months | 0 |
Supply contracts
| Supply contracts, last 12 months | ₩5.0bn |
|---|---|
| Supply contracts vs prior-year revenue | 22597.4% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 1 |
|---|---|
| DART filings, previous 3 months | 3 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
No insider transactions in the last 12 months.
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩22m | -₩45m |
| 2024 | ₩82m | -₩3m |
| 2023 | ₩267m | ₩17m |
Filing timeline
-
Access Bio signs ₩5.0bn supply contract with P&G for home tests
Access Bio filed a supply contract with The Procter & Gamble Manufacturing Company for the Flu A + Flu B + COVID-19 Combo Home Test, with a contract amount of ₩5.0bn. The filing reports this as 15.9% of revenue, and the contract period runs from Oct 15, 2026 to Oct 14, 2027.